Nektar Therapeutics appoints Diana M. Brainard, M.D. to board of directors

NEKTAR THERAPEUTICS

Dr. Brainard appointed as Class III Director effective Nov 11, 2021; term expires at 2022 annual meeting.
Board determined she is independent under SEC and Nasdaq rules.
She receives standard non-employee director compensation: initial option for 36,720 shares vesting over 3 years, RSU for 18,360 shares vesting over 3 years, and $65,000 annual cash retainer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Diana M. Brainard, M.D.

Class III Director

NKTR · NEKTAR THERAPEUTICS

Effective: 2021-11-11
Filed: November 15, 2021, 6:59 PM ET

On November 11, 2021, Diana M. Brainard, M.D. was appointed to the board of directors (the “ Board ”) of Nektar Therapeutics, a Delaware corporation (the “ Company ”), as a Class III Director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Diana M. Brainard, M.D. was appointed as Class III Director at NEKTAR THERAPEUTICS.

Action: appointed
Role: Class III Director

Exact text from the filing

On November 11, 2021, Diana M. Brainard, M.D. was appointed to the board of directors (the “ Board ”) of Nektar Therapeutics, a Delaware corporation (the “ Company ”), as a Class III Director

View on SEC.gov

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-21-059489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.